Diagnostic Utility of Auto Antibodies in Inflammatory Nerve Disorders

Emilien Delmonta,b,∗ and Hugh Willisona

Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
bReferral centre for ALS and Neuromuscular diseases, hospital La Timone, Marseille, France

Abstract
A wide range of autoantibodies have been described in immune-mediated nerve disorders that target glycans borne by glycolipids and glycoproteins enriched in the peripheral nerves. Their use as diagnostic biomarkers is very widespread, despite some limitations on sensitivity and specificity, and the lack of standardized assays and access to quality assurance schemes. Although many methods have been applied to measurement, ELISA, in the form of commercial kits or in-house assays, still remains the most widely available and convenient assay methodology.

Some antibodies have a particularly robust and widely appreciated clinical significance. Thus, the anti-MAG IgM antibodies that are found in IgM paraprotein related neuropathies define a relatively uniform clinical and prognostic phenotype. IgG antibodies against gangliosides GM1 and GD1a are strongly associated with motor axonal variants of Guillain-Barré syndrome, and anti-GQ1b with Miller Fisher syndrome. In other chronic neuropathies, antibodies against disialylated gangliosides including GD1b and GD3 are detected in ataxic neuropathies, usually associated with an IgM paraprotein, and antibodies against GM1 and the complex GM1:GalC are frequently found in multifocal motor neuropathy. Unfortunately, autoantibodies strongly associated with the diagnosis of chronic inflammatory demyelinating polyneuropathies and with demyelinating forms of GBS are still lacking.

Identification of autoantibodies that map onto a specific clinical phenotype not only allows for improved classification, but also provides better understanding of the pathophysiology of inflammatory neuropathies and the potential for therapeutic interventions.

Keywords: Inflammatory neuropathy, anti-ganglioside antibodies, anti-MAG antibodies, autoantibodies

Peripheral neuropathies are one of the most aetio logically diverse group of neurological disorders in which biomarkers and other diagnostic investigations are very widely used in both clinical classification and understanding of disease. Broadly speaking, neuropathies can be metabolic, toxic, hereditary or inflammatory, and although well recognised clinical patterns offer distinctive clues to pathological processes, diagnostic investigations also rely heavily on electrophysiological studies and biomarker screening.

With respect to biomarkers, numerous categories of auto-antibodies are able to define very specific clinical phenotypes. Although they mainly target glycans borne by glycolipids and glycoproteins, some react with intracellular or membrane-associated protein antigens. The tortuous historical evolution of the neuropathy-associated autoantibody field, combined with often poor sensitivity and specificity, does lead many to conclude that their use as diagnostic biomarkers in clinical practice is overly complicated and often unhelpful to clinical care. In this article, we review the recent advance on auto-antibodies to describe their diagnostic utility in inflammatory neuropathies and attempt to summarise the useful clinical algorithms and their pitfalls.
ANTI-GANGLIOSIDE ANTIBODIES

Gangliosides are a distinct category of glycosphin-
golipids comprising a ceramide moiety with one or
more hexose sugars that include at least one sialic acid
residue as their defining feature (Fig. 1) [1]. Many other
glycolipids that are not gangliosides, but nevertheless
share structural similarities, are also neuropathy-
associated autoantigens. The hydrophobic ceramic
tail of glycolipids (including gangliosides) are inserted
in the outer leaflet of the lipid bilayer that forms the
plasma membrane, with the hydrophilic oligosaccha-
ride moiety being displayed extracellularly, where it
can be recognised by specific antibodies. Since many
gangliosides share common structural motifs due to
common sugar sequences, a single antibody species
may have the capacity to bind multiple gangliosides.
Gangliosides are concentrated in cholesterol-enriched
microdomains of the plasma membrane termed lipid
rafts, in which they may adopt particular steric confor-
mations that either enhance or attenuate the capacity
for autoantibody recognition, depending upon the pre-
cise binding requirements for a particular antibody.
Although ubiquitous in all cells types throughout the
body, the major gangliosides are highly enriched in
axonal membranes within the peripheral nervous sys-
tem, and can be accessed by antibodies at exposed
axonal regions of the neuromuscular junction and the
node of Ranvier [2]. A limiting factor in antibody
access is also the blood nerve/brain barrier; thus gan-
glioside distribution and antibody access and binding
are discordant considerations. Indeed the absence of
CNS pathology in anti-ganglioside autoantibody states
is presumably a reflection of limited access rather than
poor antibody binding capacity, as the CNS is also very
highly enriched in gangliosides.

Anti-ganglioside antibodies can be detected
by several techniques, including enzyme-linked
immunosorbent assay (ELISA), immunodot-assay,
flow-cytometry and cell surface binding, and glyco-
array [3–6]. Wide variations in assay performance,
both within a single assay and between assays, have
been reported [4, 7], indicating that these techniques
should ideally be standardized for consistency
between different laboratories [5]. Different methods
may preferentially detect different types of antibody,
owing to variations in the orientation of the glycan
headgroup on the immobilised surface. Thus, different
techniques should not necessarily be expected to be
fully concordant with each other, and there is
no recognised optimal assay for detecting these
antibodies. ELISA remains the most commonly used
method as all laboratories are widely conversant with
this standard technology. Glyco-array is useful to
screen for many anti-ganglioside antibodies with a
small amount of serum [8].

Different anti-ganglioside antibodies are associated
with different inflammatory neuropathies (Table 1).
As a general but somewhat counter-intuitive rule, IgG
antibody isotypes are found in acute neuropathies and
IgM isotypes in chronic neuropathies. Acute motor
axonal neuropathy (AMAN) and acute motor and sen-
sory axonal neuropathy (AMSAN) represent about
10% of the Guillain-Barré syndrome in Western coun-
tries and are strongly associated with IgG antibodies
against GM1 and GD1a, and structurally similar but
quantitatively minor a-series gangliosides (e.g. GM1b
and GalNAcGD1a) [9]. The diagnosis of acute neu-
ropathy with a pharyngeal-cervical-brachial pattern
of weakness (PCB) or pure oropharyngeal palsy is
supported by the detection of IgG antibodies against
GT1a that may or may not also react with GQ1b. Miller Fisher syndrome, characterized by acute-onset
areflexia, ataxia, ophthalmoplegia is associated with
IgG anti-GQ1b antibodies [10]. Bickerstaff brainstem
encephalitis and incomplete forms of Miller Fisher
syndrome (MFS), as acute ophthalmoplegia, are also
associated with IgG anti-GQ1b antibodies. Antibodies
found in acute sensory ataxic neuropathy are directed
against either GQ1b or GD1b [11]. The strong associa-
tion of anti-GQ1b and related disialylated ganglioside
antibodies with the above regional forms of GBS
have led to the concept of ‘the anti-GQ1b antibod-
ies syndromes’ as an umbrella term for MFS and its
myriad of forms frustes [10–12]. It is noteworthy that
false positive anti-GQ1b antibody assays, occurring
| Neurpathy                      | Main clinical features          | Associated antibodies                        |
|-------------------------------|---------------------------------|----------------------------------------------|
| AMAN                          | Acute                           | IgG anti-GM1, GD1a                            |
| Miller Fisher syndrome        | Ataxia and ophthalmoplegia      | IgG anti-GQ1b, GT1a                           |
| Acute sensory ataxic neuropathy| Sensory, ataxia                 | IgG anti-GD1b or GQ1b                        |
| PCB                           | Motor                            | IgG anti-GT1a or GQ1b                        |
| MMN                           | Chronic                          | IgM anti-GM1, complex GM1:GalC               |
| CANOMAD and CANDA             | Sensory, ataxia                  | IgM anti-GD1b, GT1b, GT1a, GQ1b              |
| CIDP                          | Sensory motor                    | Anti NF155, NF186, contactin                 |
| Paraneoplastic neuropathy     | Sensory ataxia or sensory motor  | Anti Hu, anti CV2                            |
| Anti MAG neuropathy           | Sensory, ataxia                  | Monoclonal IgM anti MAG                      |

AMAN, acute motor axonal neuropathy; PCB, pharyngeal-cervical-brachial weakness; MMN multifocal motor neuropathy with conduction blocks; CANOMAD, chronic ataxic neuropathy-ophthalmoplegia-IgM paraprotein anti disialosyl antibodies; CANDA, chronic ataxic neuropathy with disialosyl antibodies; CIDP, chronic inflammatory demyelinating polyneuropathy; GM-GalC complex of GM1 and galactocerebroside (GalC); NF, neurofascin; MAG, myelin associated glycoprotein.

in other disease or control populations are extremely uncommon.

Multifocal motor neuropathy (MMN) is a chronic neuropathy featuring pure motor weakness and motor conduction blocks on neurophysiological testing [13]. IgM antibodies against GM1 are found in around half of the MMN sera. A high titre may be associated with a more severe disease [14]. The diagnosis of CANOMAD (chronic ataxic neuropathy-ophthalmoplegia-IgM paraprotein anti disialosyl antibodies) rests on the detection of an IgM monoclonal gammopathy reacting against disialosyl gangliosides (principally GD3, GD1b, GT1b and GQ1b) [15]. The gammopathy may be of a small amount, requiring immunofixation of the sera to be detected. Intravenous immunoglobulins may be therapeutically effective in MMN and in chronic sensory ataxic neuropahties associated with IgM anti GD1b antibodies, with or without IgM monoclonal gammopathy [16]. Antibodies involved in MFS and PCB tend to preferentially react with the terminal disialosyl structure shared by GQ1b and GT1a (Fig. 1), whereas antibodies involved in CANOMAD also react with the internal disialosyl structure [11, 15].

The relevance of antibodies against complexes of gangliosides has been recently stressed and this remains a highly active field of research. As new data emerges, this difficult field will hopefully undergo some clarification. Ganglioside complexes in this context are defined as interacting partnerships between 2 structurally distinct gangliosides (e.g. GM1 and GD1a) that create new antibody binding sites when in heteromeric complex, that are not present in either individual ganglioside when presented alone [8]. Anti-ganglioside complex antibodies are more frequently detected in Guillain-Barré syndrome than antibodies against single gangliosides [17–19]. Antibodies against complexes of GM1 and galactocerebroside (GM1:GalC) appear to be a more sensitive marker than antibodies against GM1 alone for the diagnosis of MMN [6, 20–22]. The precise mechanisms underlying antibody-complex interaction require further study; however the currently held view is that complexes of gangliosides may enhance antibody detection by one or both of two mechanisms. Either both component of the complex of gangliosides can form a heterodimer that generates a new epitope, or the cis-interaction between the gangliosides can result in a preferential presentation of an epitope present on one or other of the partners in the complex [23].

Anti-ganglioside antibodies are thought to be the principle pathogenic driver of the disease in which they are found, on the basis of a substantial body of evidence accumulated over many years, which is briefly summarised here. Cases of AMAN have been reported after the administration of ganglioside [24]. Campylobacter jejuni, the most common predisposing agent in GBS and MFS, has surface lipooligosaccharides (LOS) that are structural mimics of mammalian gangliosides including GM1, GD1a and GT1a/GQ1b [25, 26]. This strongly favours the hypothesis that molecular mimicry between LOS and gangliosides underpins the autoimmune process [27]. Sensitization of experimental rabbits with GD1b or GM1 has induced an experimental inflammatory neuritis with ataxic or motor dominant components respectively, mirroring the human clinical counterparts [28, 29]. Anti ganglioside antibodies are able to bind the nerve roots, the pre-synaptic motor nerve terminal, the nodes of Ranvier and dorsal root ganglion neuronal cell bodies [30, 31]. Binding of the antibodies activates complement leading to the formation of the highly neurotoxic membrane attack complex. Voltage-gated sodium channels clusters disappear through calpain.
cleavage, axo-glial junctions are disrupted at the nodes of Ranvier and failure of conduction occurs (reversible conduction block). If the immunopathological process progresses, axonal degeneration may occur. There is growing opinion that many features of the anti-ganglioside antibody-mediated neuropathies can be encompassed in a new categorisation referred to as the nodo-paranodopathy [32, 33]. As our experimental knowledge grows, it is becoming increasing difficult to clinically and electrophysiologically distinguish reversible axonal conduction block from that caused by paranodal demyelination, especially since both may occur concurrently in the same nerve fibre.

**ANTI-MYELIN ASSOCIATED GLYCOPROTEIN (MAG) ANTIBODIES**

Anti-MAG antibodies are detected in half of IgM paraproteinaemic neuropathy cases [34]. In the remaining cases there is no uniform autoantibody specificity. Patients with anti-MAG neuropathy have highly characteristic distal, chronic, slowly progressive sensory involvement with ataxia and often tremor. Muscular weakness is mild or absent even in the presence of motor demyelination [35, 36]. Some patients may have atypical clinical features, as proximal weakness and sub-acute progression, which can mimic chronic inflammatory demyelinating polyneuropathy (CIDP) [36]. Nerve conduction studies show a predominantly distal demyelinating neuropathy with prolonged distal motor latencies and generally absent sensory nerve action potentials [37].

ELISA is considered more sensitive than Westernblot to detect anti MAG antibodies [38]. However, ELISA may be less specific if the titre is between 1000 and 10000, possibly because of some cross-reactivity with GM1 and disialyl gangliosides [39]. There is no association between the anti-MAG antibodies titres and the clinical features of the patients [35, 40, 41]. In general, anti-MAG neuropathy does not respond well to any treatment, and many patients remain untreated, often after several trials of failed or insufficiently successful therapy [42–44]. The correlation between anti-MAG antibody titre and the efficiency of Rituximab therapy (an anti-CD20) is an equivocal finding, as improvement after therapy has been associated with either high or low anti MAG titres [44, 45]. There is an expectation that once new therapies emerge that target the long lived plasma cells that are believed to be the source of anti-MAG antibodies, there may be a reasonable prospect of a successful treatment regime. This would also apply to other paraproteinaemic neuropathies.

MAG is an integral membrane glycoprotein enriched in periaxonal Schwann cell membranes, paranodal loops and Schmit-Lanterman incisures, and member of the immunoglobulin superfamily. The antigenic region of the MAG molecule for the IgM antibodies found in affected humans is the human natural killer-1 (HNK-1) carbohydrate epitope, which comprises an unusual glucoronic acid that is 3-sulphated. The HNK-1 epitope is also present in other peripheral nerve glycoproteins, including PO, PMP-22 and phosphocan and thus the in vivo target for the human antibodies may reside on multiple nerve molecules. Furthermore, 2 peripheral nerve glycolipids, sulphated glucuronyl paragloboside (SGPG), and its higher lactosaminyl homologue (SOLPG) also bear the antigenic determinant. Therefore, patients with anti MAG neuropathy may have antibodies against SGPG and other glycoconjugated structures of the myelin sheaths. Extension of antibody reactivity to various HNK-1 bearing proteins other than MAG, might be associated with treatment resistance [40]. Some ‘anti-MAG’ antibodies also react with sulphatides (3-sulphated galactocerebroside) [46]. It is also noteworthy that some cases of CIDP may harbour anti-SGPG antibodies [47].

**OTHER ANTIBODIES ASSOCIATED WITH INFLAMMATORY NEUROPATHIES**

Several proteins of the nodal and paranodal domains have recently been identified as possible target in inflammatory neuropathy sera [9]. Antibodies against neurofascin (NF) 186 or gliomedin have been found in 62% of 53 MMN patients. Ten percent of these MMN sera without IgM anti GM1 reactivity had anti NF186 antibodies [48]. Antibodies against NF 186, NF 155, LM1 and contactin are detected in less than 5% of CIDP sera [49–52]. Anti-moesin antibodies have been identified in GBS subsequent to CMV infection [53, 54]. As these antibodies are infrequent, they are not necessarily good biomarkers for screening inflammatory neuropathy sera, but they are nevertheless of major interest to explain the pathophysiology of the cases in which they are found. Extensive ongoing work is characterising these phenotypes in animal models [9, 55].

**IN CLINICAL PRACTICE**

The diagnostic utility of anti-nerve auto-antibodies is often limited by their modest sensitivity and by the lack of standardized assays. ELISA remains the most...
REFERENCES

CONFLICT OF INTEREST

The authors have no conflict of interest to report.

REFERENCES

[1] Svenningholm L. Designation and schematic structure of gangliosides and allied glycosphingolipids. Prog Brain Res. 1994;101:XX-XIV.

[2] Pomp JJ, Willison HJ. Pathophysiologic actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction. J Physiol. 2009;587(6):3979-3999.

[3] Escande-Beillard N, David, MJ, Portoukalian J, Pouget J. GM1 ganglioside complexes as modulators of autoantibody and lectin binding. J Neurol. 2013;20(1):62-70.

[4] Caudie C, Quittard Pinon A, Bouhour F, Vial C, Garnier L, Fabien N. Comparison of commercial tests for detecting multiple anti-ganglioside antibodies in patients with well-characterised immune-mediated peripheral neuropathies. Clin Lab. 2013;59(11-12):1277-1287.

[5] Willison HJ, Yuki N, Uncini A. Acute and chronic ataxic neuropathies with disialosyl antibodies: A continuous clinical spectrum and a common pathophysiological mechanism. Muscle Nerve. 2014;49(5):629-635.

[6] Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125:2591-2625.

[7] Van Schaik IN, Bossuyt PMM, Brand A, Vermeulen M. Diagnostic value of GM1 antibodies in motor neuron disorders and neuromyotonia: A meta-analysis. Neurology. 1995;45(8):1570-1577.

[8] Galban-Horcajo F, Halstead SK, McGonigal R, Willison HJ. The application of glycosphingolipid arrays to autoantibody detection in neuroimmunological disorders. Curr Opin Chem Biol. 2014;18:78-86.

[9] Lim JP, Devere J, Yuki N. Peripheral nerve proteins as potential autoantigens in acute and chronic inflammatory demyelinating polyneuropathies. Autonom Rev. 2014;14(10):1070-1078.

[10] Wakerley BR, Uncina A, Yuki N, Guillain-Barre and Miller Fisher syndromes–new diagnostic classification. Nat Rev Neurol. 2014;10(9):537-544.

[11] Yuki N, Uncina A. Acute and chronic ataxic neuropathies with disialosyl antibodies: A continuous clinical spectrum and a common pathophysiological mechanism. Muscle Nerve. 2014;49(5):629-635.

[12] Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125:2591-2625.

[13] Guimarães-Coza R, Bombelli F, Leger J-M. Multifocal motor neuropathy. Curr Opin Neurol. 2013;26(5):503-509.

[14] Cate EA, Jacobs BC, Yuki N, Teo-Gillen AF, Preprez H, Franssen H, et al. Multifocal motor neuropathy: Association of anti-GM1 IgM antibodies with clinical features. Neurology. 2010;75(22):1961-1967.

[15] Willison HJ, O’Leary CP, Yezhav J, Blumkaoni L, Bubby M, Donoughy M, et al. The clinical and laboratory features of chronic inflammatory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain. 2001;124:1998-1977.

[16] Attarian S, Boucraut J, Hubert AM, Uzzone D, Delmont E, Verschueren A, et al. Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: Response to IV Ig therapy. J Neurol Neurosurg Psychiatry. 2009;80(1):61-64.

[17] Kaidi K, Montia D, Karasik M, Kamakura K, Motoyoshi K, Hirakawa M, et al. Ganglioside complexes as new targets antigens in Guillain-Barré syndrome. Ann Neurol. 2004;56:557.

[18] Rinaldi S, Brennan KM, Kaha G, Walgaard C, van Doorn P, Jacobs BC, et al. Antibodies to heteromeric glycolipid complexes in guillain-barré syndrome. Plas. One. 2013;8(12):e2337.

[19] Shabtai-Niala N, Keshavan N, Sawa S, Unapakhi T, Chun Y-C, Kowalha S, et al. Antibodies to single glycocephalas and glycolipid complexes in guillain-Barré syndrome subtypes. Neurology. 2014;83(2):118-124.

[20] Nobale-Ornario E, Giannotta C, Musset L, Mesina P, Leger J-M. Sensitivity and predictive value of anti-GM1/galactocerebroside IgM antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2014;85(7):754-758.

[21] Pestronk A, Choksi R, Blumer G, Lopate G. Multifocal motor neuropathy: Serum IgM binding to a GM1 ganglioside-containing lipid mixture but not to GMI alone. Neurology. 1997;48(6):1104-1106.

[22] Galban-Horcajo F, Fitzpatrick AM, Hutton AJ, Dunn SM, Kaha G, Brennan KM, et al. Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy. Eur J Neurosci. 1999;9(6):71-77.

[23] Delmont E, Halstead S, Galban-Horcajo F, Yao D, Desmalle C, Willison H. Improving the detection of IgM antibodies against glycosphingolipids complexes of GM1 and Galactocerebroside in Multifocal Motor Neuropathy using glycosphingolipid and ELISA assays. J Neuroimmunol. 2014;274:159-161.

[24] van Schaik IN, Bossuyt PMM, Breind A. Vemodicidu M. Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: A meta-analysis. Neurology. 1995;45(8):1570-1577.

[25] Yuki N, Susuki K, Koga M, Nishimoto Y, Okada M, Hirata K, et al. Carbohydrate mimicry between human ganglioside...
GMI and Campylobacter jejuni lipopolysaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci U S A. 2004;101(3):11464-11469.

[26] Jacobs BC, O’Hanlon GM, Brennan EG, Veitch J, van Doorn PA, Williamson SD. Human IgM paraproteins demonstrate shared reactivity between Campylobacter jejuni lipopolysaccharides and human peripheral nerve disialylated gangliosides. J Neuroimmunol. 1997;78(1-2):23-30.

[27] Caporale CM, Caspaso M, Luciani M, Prencipe V, Cricenti R, Grandi P et al. Experimental axonopathy induced by immunization with Campylobacter jejuni lipopolysaccharide from a patient with Guillain-Barré syndrome. J Neuroimmunol. 2006;174(1-2):12-20.

[28] Kusunoki S, Shemau J, Chiba A, Ugozo Y, Hitoole S, Kanazawa J. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol. 1996;39(4):423-431.

[29] Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GMI ganglioside. Ann Neurol. 2001;49(6):712-720.

[30] Fewou SN, Plomp JJ, Willison HJ. The pre-synaptic motor nerve terminal as a site for antibody-mediated neurotoxicity in autoimmune neuropathies and synaptopathies. J Anat. 2014;224(1):96-114.

[31] Santos R, Uncini A, Corbo M, Stanggitis SM, Thomas FP, Hays AP et al. Experimental conduction block induced by serum from a patient with anti-GMI antibodies. Ann Neurol. 1992;31(4):385-390.

[32] Uncini A, Suzuki K, Yuki N, Ondo-paranodopathy: Beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neuropathol. 2013;12(4):1928-1934.

[33] Miller JL, Spyrigou A, Jaros E, Gillan-Jurcso F, Inflammatory Bowel Disease and Anti-GQBP ganglioside positive Miller Fisher syndrome – evidence of paraneoplastic pathology on nerve biopsy. J Neuropathol Dis. 2014;1:191-195.

[34] Nobile-Orozco E, Manfredini E, Caspo M, Mercisi N, Monaco S, Ferrara S et al. Frequency and clinical correlates of anti-ganglioside M antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol. 1994;36(5):416-424.

[35] Lunn MPT, Nobile-Orazio E. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 2016;276(1-2):207-212.

[36] Lunn MPT, Nobile-Orazio E. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 2016;276(1-2):207-212.

[37] Kusunoki S. Clinical features of CIDP with LM1-associated GMI antibodies. J Neuroimmunol. 2014;276(1-2):207-212.

[38] Kusunoki S. Clinical features of CIDP with LM1-associated GMI antibodies. J Neuroimmunol. 2014;276(1-2):207-212.

[39] L ´eger J-M, Viala K, Nicoia G, Cr ´eange A, Vallat J-M, Pouget J, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013;80:2217-2225.

[40] Dalsak MC, Rakovicov´e, G, Salagergh M, Dambrovski MM, Hahn AF, Raga R et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65(3):286-293.

[41] Beneditti B, Briani C, Grandi M, Vige T, Gibelli M, Ghiglione E et al. Predictors of response to rituximab in patients with neuropathy and anti-myelin-associated glycoprotein immunoglobulin M. J Peripher Nerv Syst. 2007;12(2):102-107.

[42] Giannotti C, Di Patro D, Gallia J, Nobile-Orozco E. Anti-sulfatide IgM antibodies in peripheral neuropathy: To test or not test? Eur Neurol. 2015; doi: 10.1159/2015.088 [Epub ahead of print].

[43] Yuki N, Tagawa Y, Haneda S. Autoantibodies to peripheral nerve glycophospholipid SPG, SLPG, and SGP in Guillain- Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 1996;70(1):1-6.

[44] Nuttulo F, N, F, Di Felice F, Yuki N, Rosados Rodriguez BM, Corti D, Nobile-Orozco E et al. Autoantibodies to neurofascin-186 and glicerin in multivisceral motor neurone disease. J Neuroimmunol. 2014;276(1-2):207-212.

[45] Qureshi N, Nogales-Gaule G, Rojas-Garcia R, Martinez-Hernandez E, Diaz-Manera J, Suzuki-Carvajal X et al. Antibodies to contactins in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 2013;276(1-2):370-380.

[46] Ng I, Kikuta I, Kawakami T, Tanaka T, Shimada M, Obata T. Moesin is a possible target molecule for anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Neurology. 2012;78(3):2241-2248.

[47] Kusunoki S, Suzuki H, Samukawa M, Hamada Y, Takada K, Kusunoki S. Clinical features of CIDP with LM1-associated GMI antibodies. J Neurol Neurosurg Psychiatry. 2013;84(5):573-575.

[48] Qureshi N, Nogales-Gaule G, Rojas-Garcia R, Diaz-Manera J, Pardo J, Obega-Mormo A, Sedano MJ, Gallardo E, Berciano J, Ibiza R, Dalmau J, Illa J. Neurofascin IgM antibodies in CEDP associate with disabling tremor and poor response to IVIg. Neurology. 2014;82(10):879-886.

[49] Sawat S, Satoh M, Mori M, Misawa S, Sugawara K, Kuzumi T et al. Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome. Neurol. 2014;83(1):112-117.

[50] Willison H, Scherer SS. Ramvith revisited: Novel nodal antigen stimulate interest in GBS pathogenesis. Neurology. 2014;83(2):108-109.

[51] Desmazieres A, Zonta B, Zhang A, Wu L-MN, Sherman DL, Brophy P. Differential stability of PNS and CNS nodal complexes when neuronal neurofascin is lost. J Neurosci. 2014;34(14):5083-5088.